Is CGEM or TNGX more profitable?

Tango Therapeutics' return on equity of -41.54% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -52.89% -48.18% Tango Therapeutics N/A -41.54% -33.44%

Does the media favor CGEM or TNGX?

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Tango Therapeutics. MarketBeat recorded 6 mentions for Cullinan Therapeutics and 5 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.50 beat Cullinan Therapeutics' score of 0.16 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tango Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, CGEM or PBLS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.10 N/A Parabilis Medicines N/A N/A N/A N/A N/A

Is CGEM or PBLS more profitable?

Parabilis Medicines' return on equity of 0.00% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -52.89% -48.18% Parabilis Medicines N/A N/A N/A

Which has better valuation and earnings, VKTX or CGEM?

Viking Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viking Therapeutics N/A N/A -$359.64M -$4.66 N/A Cullinan Therapeutics N/A N/A -$219.88M -$3.10 N/A

Is VKTX or CGEM more profitable?

Cullinan Therapeutics' return on equity of -52.89% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Viking Therapeutics N/A -94.56% -82.75% Cullinan Therapeutics N/A -52.89% -48.18%

Does the media favor VKTX or CGEM?

In the previous week, Viking Therapeutics had 4 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 10 mentions for Viking Therapeutics and 6 mentions for Cullinan Therapeutics. Viking Therapeutics' average media sentiment score of 1.23 beat Cullinan Therapeutics' score of 0.16 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CGEM or DNLI more profitable?

Cullinan Therapeutics' return on equity of -52.89% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -52.89% -48.18% Denali Therapeutics N/A -55.27% -44.24%

Does the media refer more to CGEM or DNLI?

In the previous week, Denali Therapeutics had 5 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 11 mentions for Denali Therapeutics and 6 mentions for Cullinan Therapeutics. Denali Therapeutics' average media sentiment score of 0.31 beat Cullinan Therapeutics' score of 0.16 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Denali Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CGEM or RLAY more profitable?

Relay Therapeutics' return on equity of -47.23% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -52.89% -48.18% Relay Therapeutics N/A -47.23% -43.10%

Does the media refer more to CGEM or RLAY?

In the previous week, Relay Therapeutics had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 7 mentions for Relay Therapeutics and 6 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.16 beat Relay Therapeutics' score of 0.14 indicating that Cullinan Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relay Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Cullinan Therapeutics (CGEM) Competitors

$17.73 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$17.40 -0.33 (-1.86%)

As of 07:40 AM Eastern

Compare

CGEM vs. TNGX, PBLS, VKTX, DNLI, and RLAY

Should you buy Cullinan Therapeutics stock or one of its competitors? MarketBeat compares Cullinan Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cullinan Therapeutics include Tango Therapeutics (TNGX), Parabilis Medicines (PBLS), Viking Therapeutics (VKTX), Denali Therapeutics (DNLI), and Relay Therapeutics (RLAY). These companies are all part of the "biotechnology" industry.

How does Cullinan Therapeutics compare to Tango Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Cullinan Therapeutics has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

Cullinan Therapeutics presently has a consensus target price of $32.14, suggesting a potential upside of 81.29%. Tango Therapeutics has a consensus target price of $42.15, suggesting a potential upside of 55.72%. Given Cullinan Therapeutics' higher possible upside, research analysts plainly believe Cullinan Therapeutics is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Tango Therapeutics. MarketBeat recorded 6 mentions for Cullinan Therapeutics and 5 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.50 beat Cullinan Therapeutics' score of 0.16 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics' return on equity of -41.54% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-52.89%	-48.18%
Tango Therapeutics	N/A	-41.54%	-33.44%

Tango Therapeutics has higher revenue and earnings than Cullinan Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A
Tango Therapeutics	$62.38M	62.77	-$101.59M	-$0.83	N/A

Summary

Tango Therapeutics beats Cullinan Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Parabilis Medicines?

Cullinan Therapeutics (NASDAQ:CGEM) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

In the previous week, Cullinan Therapeutics had 6 more articles in the media than Parabilis Medicines. MarketBeat recorded 6 mentions for Cullinan Therapeutics and 0 mentions for Parabilis Medicines. Cullinan Therapeutics' average media sentiment score of 0.16 beat Parabilis Medicines' score of 0.00 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cullinan Therapeutics	Neutral
Parabilis Medicines	Neutral

Cullinan Therapeutics currently has a consensus price target of $32.14, indicating a potential upside of 81.29%. Parabilis Medicines has a consensus price target of $41.67, indicating a potential upside of 19.12%. Given Cullinan Therapeutics' higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Parabilis Medicines' return on equity of 0.00% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-52.89%	-48.18%
Parabilis Medicines	N/A	N/A	N/A

86.3% of Cullinan Therapeutics shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Cullinan Therapeutics beats Parabilis Medicines on 6 of the 10 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Cullinan Therapeutics (NASDAQ:CGEM) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

In the previous week, Viking Therapeutics had 4 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 10 mentions for Viking Therapeutics and 6 mentions for Cullinan Therapeutics. Viking Therapeutics' average media sentiment score of 1.23 beat Cullinan Therapeutics' score of 0.16 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viking Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

Cullinan Therapeutics' return on equity of -52.89% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
Cullinan Therapeutics	N/A	-52.89%	-48.18%

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Viking Therapeutics currently has a consensus price target of $97.88, suggesting a potential upside of 185.68%. Cullinan Therapeutics has a consensus price target of $32.14, suggesting a potential upside of 81.29%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Viking Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Viking Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A

Summary

Viking Therapeutics and Cullinan Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Denali Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Cullinan Therapeutics' return on equity of -52.89% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-52.89%	-48.18%
Denali Therapeutics	N/A	-55.27%	-44.24%

Cullinan Therapeutics has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

Cullinan Therapeutics currently has a consensus target price of $32.14, suggesting a potential upside of 81.29%. Denali Therapeutics has a consensus target price of $35.92, suggesting a potential upside of 44.65%. Given Cullinan Therapeutics' higher possible upside, analysts plainly believe Cullinan Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cullinan Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A
Denali Therapeutics	$330.53M	11.92	-$512.54M	-$2.84	N/A

In the previous week, Denali Therapeutics had 5 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 11 mentions for Denali Therapeutics and 6 mentions for Cullinan Therapeutics. Denali Therapeutics' average media sentiment score of 0.31 beat Cullinan Therapeutics' score of 0.16 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Denali Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Denali Therapeutics beats Cullinan Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Relay Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Cullinan Therapeutics has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A
Relay Therapeutics	$15.35M	282.24	-$276.48M	-$1.57	N/A

Relay Therapeutics' return on equity of -47.23% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-52.89%	-48.18%
Relay Therapeutics	N/A	-47.23%	-43.10%

Cullinan Therapeutics currently has a consensus price target of $32.14, suggesting a potential upside of 81.29%. Relay Therapeutics has a consensus price target of $25.17, suggesting a potential upside of 27.30%. Given Cullinan Therapeutics' higher possible upside, equities analysts clearly believe Cullinan Therapeutics is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86

Cullinan Therapeutics has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market.

In the previous week, Relay Therapeutics had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 7 mentions for Relay Therapeutics and 6 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.16 beat Relay Therapeutics' score of 0.14 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relay Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Relay Therapeutics beats Cullinan Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Cullinan Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGEM vs. The Competition

Export

Metric	Cullinan Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.14B	$3.69B	$7.00B	$12.99B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-5.72	9.02	270.61	25.05
Price / Sales	N/A	1,287.31	657.91	107.93
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	2.56	17.69	11.26	6.43
Net Income	-$219.88M	-$13.25M	$3.45B	$348.10M
7 Day Performance	9.11%	5.04%	3.41%	2.66%
1 Month Performance	-2.21%	-2.10%	-0.71%	-0.85%
1 Year Performance	142.88%	61.50%	77.43%	23.96%

Cullinan Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGEM Cullinan Therapeutics	2.6779 of 5 stars	$17.73 flat	$32.14 +81.3%	+142.9%	$1.14B	N/A	N/A	30	Earnings Report Gap Up
TNGX Tango Therapeutics	2.2655 of 5 stars	$28.82 +5.9%	$42.15 +46.3%	+309.5%	$4.16B	$62.38M	N/A	90	Upcoming Earnings Gap Up
PBLS Parabilis Medicines	2.4828 of 5 stars	$34.89 +2.7%	$41.67 +19.4%	N/A	$4.12B	N/A	N/A	N/A	Positive News
VKTX Viking Therapeutics	3.5652 of 5 stars	$33.38 +2.4%	$97.88 +193.2%	-9.6%	$3.88B	N/A	N/A	20
DNLI Denali Therapeutics	2.7515 of 5 stars	$24.07 +4.0%	$35.17 +46.1%	+77.9%	$3.82B	$330.53M	N/A	430	Earnings Report Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGEM) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. TNGX, PBLS, VKTX, DNLI, and RLAY

How does Cullinan Therapeutics compare to Tango Therapeutics?

Summary

How does Cullinan Therapeutics compare to Parabilis Medicines?

Summary

How does Cullinan Therapeutics compare to Viking Therapeutics?

Summary

How does Cullinan Therapeutics compare to Denali Therapeutics?

Summary

How does Cullinan Therapeutics compare to Relay Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. TNGX, PBLS, VKTX, DNLI, and RLAY

How does Cullinan Therapeutics compare to Tango Therapeutics?

Which has more volatility and risk, CGEM or TNGX?

Do analysts prefer CGEM or TNGX?

Do insiders and institutionals hold more shares of CGEM or TNGX?

Does the media favor CGEM or TNGX?

Is CGEM or TNGX more profitable?

Which has better valuation and earnings, CGEM or TNGX?

Summary

How does Cullinan Therapeutics compare to Parabilis Medicines?

Which has preferable earnings and valuation, CGEM or PBLS?

Does the media favor CGEM or PBLS?

Do analysts recommend CGEM or PBLS?

Is CGEM or PBLS more profitable?

Do insiders and institutionals have more ownership in CGEM or PBLS?

Summary

How does Cullinan Therapeutics compare to Viking Therapeutics?

Does the media favor VKTX or CGEM?

Which has more volatility & risk, VKTX or CGEM?

Is VKTX or CGEM more profitable?

Do insiders & institutionals hold more shares of VKTX or CGEM?

Do analysts recommend VKTX or CGEM?

Which has better valuation and earnings, VKTX or CGEM?

Summary

How does Cullinan Therapeutics compare to Denali Therapeutics?

Is CGEM or DNLI more profitable?

Which has more volatility and risk, CGEM or DNLI?

Do analysts rate CGEM or DNLI?

Do insiders & institutionals hold more shares of CGEM or DNLI?

Which has better valuation & earnings, CGEM or DNLI?

Does the media refer more to CGEM or DNLI?

Summary

How does Cullinan Therapeutics compare to Relay Therapeutics?

Which has stronger earnings and valuation, CGEM or RLAY?

Is CGEM or RLAY more profitable?

Do analysts prefer CGEM or RLAY?

Which has more risk and volatility, CGEM or RLAY?

Does the media refer more to CGEM or RLAY?

Do institutionals and insiders hold more shares of CGEM or RLAY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools